128133-59-5

Usage

Uses

Used in Pharmaceutical Industry:
1-(Benzyloxy)-3-ethynylbenzene is used as a key intermediate for the synthesis of pharmaceutical compounds. Its unique structure allows for the development of new drugs with potential therapeutic applications.
Used in Agrochemical Industry:
In the agrochemical sector, 1-(Benzyloxy)-3-ethynylbenzene is utilized as a precursor in the production of various agrochemicals, contributing to the development of effective pesticides and other agricultural chemicals.
Used in Materials Science:
1-(Benzyloxy)-3-ethynylbenzene is employed in materials science for the synthesis of advanced materials with specific properties. Its versatility in organic synthesis enables the creation of materials with tailored characteristics for various applications.

InChI:InChI=1/C15H12O/c1-2-13-9-6-10-15(11-13)16-12-14-7-4-3-5-8-14/h1,3-11H,12H2

Upstream product

• 10401-11-3 3-hydroxy phenylacetylene 
• 100-39-0 benzyl bromide 
• 626-02-8 3-Iodophenol 
• 388061-72-1 3-[2-(trimethylsilylethynyl)]phenol 
• 177259-98-2 2-[(3-(benzyloxy)phenyl)]ethan-1-ol 
• 100-44-7 benzyl chloride 

Downstream Products

• 141976-47-8 1-phenyl-3-(3-benzyloxyphenyl)-2-propyne-1-one 
• 173098-21-0 1-Ethenyl-3-(phenylmethoxy)benzene 
• 620-18-8 3-hydroxystyrene 
• 668477-50-7 1-(benzyloxy)-3-ethylbenzene 
• 185995-59-9 1-(3-hydroxyphenyl)-2-(3,4-diphenylphenyl)ethane 
• 185994-78-9 methyl 2-{3-[2-(3,4-diphenylphenyl)ethan-1-yl]phenoxy}acetate 
• 1356496-95-1 (3-benzyloxy-3',4'-diphenyl)diphenylacetylene 
• 1618099-63-0 (E)-2-(3-(benzyloxy)styryl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane 
• 1203610-65-4 5-[3-[(phenyl)methoxy]phenyl]-3-isoxazolecarboxylic acid ethyl ester 

Relevant academic research and scientific papers

Synthesis and preliminary evaluation of 4-hydroxy-6-(3-[11C]methoxyphenethyl)pyridazin-3(2H)-one, a 11C-labeled D-amino acid oxidase (DAAO) inhibitor for PET imaging

Selective DAAO inhibitors have demonstrated promising therapeutic effects in clinical studies, including clinically alleviating symptoms of schizophrenic patients and ameliorating cognitive function in Alzheimer's patients with early phase. Herein we repo

BTK Inhibitors and uses thereof

The invention discloses a bruton's tyrosine kinase (BTK) inhibitor and use thereof. Specifically, the invention provides heteroaromatic compounds or stereoisomers, geometrical isomers, tautomers, racemates, nitrogen oxides, hydrates, solvates, metabolites and pharmaceutically acceptable salts or prodrugs thereof, and pharmaceutical compositions containing the heteroaromatic compounds; the invention also discloses use of the heteroaromatic compounds or the pharmaceutical compositions containing the heteroaromatic compounds in preparation of medicines; the medicines can be used for treating autoimmune diseases, inflammatory diseases or proliferative diseases.

SO2F2-Mediated Oxidative Dehydrogenation and Dehydration of Alcohols to Alkynes

Direct synthesis of alkynes from inexpensive, abundant alcohols was achieved in high yields (greater than 40 examples, up to 95% yield) through a SO2F2-promoted dehydration and dehydrogenation process. This straightforward transformation of sp3-sp3 (C-C) bonds to sp-sp (C=C) bonds requires only inexpensive and readily available reagents (no transition metals) under mild conditions. The crude alkynes are sufficiently free of impurities to permit direct use in further transformations, as illustrated by regioselective Huisgen alkyne-azide cycloaddition reactions with PhN3 to give 1,4-substituted 1,2,3-traiazoles (16 examples, up to 92% yield) and Sonogashira couplings (10 examples, up to 77% yield).

Varying Chirality Across Nicotinic Acetylcholine Receptor Subtypes: Selective Binding of Quinuclidine Triazole Compounds

The novel quinuclidine anti-1,2,3-triazole derivatives T1-T6 were designed based on the structure of QND8. The binding studies revealed that the stereochemistry at the C3 position of the quinuclidine scaffold plays an important role in the nAChR subtype selectivity. Whereas the (R)-enantiomers are selective to α7 over α4β2 (by factors of 44-225) and to a smaller degree over α3β4 (3-33), their (S)-counterparts prefer α3β4 over α4β2 (62-237) as well as over α7 (5-294). The (R)-derivatives were highly selective to α7 over α3β4 subtypes compared to (RS)- and (R)-QND8. The (S)-enantiomers are 5-10 times more selective to α4β2 than their (R) forms. The overall strongest affinity is observed for the (S)-enantiomer binding to α3β4 (Ki, 2.25-19.5 nM) followed by their (R)-counterpart binding to α7 (Ki, 22.5-117 nM), with a significantly weaker (S)-enantiomer binding to α4β2 (Ki, 414-1980 nM) still above the very weak respective (R)-analogue affinity (Ki, 5059-10436 nM).

Rational design of 5-phenyl-3-isoxazolecarboxylic acid ethyl esters as growth inhibitors of Mycobacterium tuberculosis. A potent and selective series for further drug development

New antituberculosis (anti-TB) drugs are urgently needed to shorten the 6-12month treatment regimen and especially to battle drug-resistant Mycobacterium tuberculosis (Mtb) strains. In this study, we have continued our efforts to develop isoxazole-based a

Amino-5-(5-membered)hetero-arylimidazolone compounds and the use thereof for beta-secretase modulation

The present invention provides a 2-amino-5-heteroaryl-5-phenylimidazolone compound of formula I The present invention also provides methods for the use thereof to inhibit β-secretase (BACE) and treat β-amyloid deposits and neurofibrillary tangles

Calcium uptake inhibitors

This invention relates to 1-phenyl-3-phenyl-2-propyne-1-ones, the use of these compounds as calcium uptake inhibitors in leukocytes and thrombocytes, and pharmaceutical compositions containing these compounds as active ingredients, and the process of their preparation.